#Congenital adrenal hyperplasia

18 Oct 2026

OMass Raises $310 Million to Advance CAH Drug

UK biotech OMass Therapeutics secures $310 million to push its MC2‑blocking drug into Phase 2 trials for congenital adrenal hyperplasia.

Read more